8-K filing — Aclaris Therapeutics, Inc. (ACRS)
Filed: 2026-11-05 AccNo: 0001104659-26-123039 Size: 372 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics announced its Q3 2026 financial results and provided updates on its clinical pipeline, including progress on Modzatinib, Bosakitug, and ATI-052.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Canaccord Genuity Raises Price Target for Aclaris Therapeutics
Canaccord Genuity has maintained its 'Buy' rating on Aclaris Therapeutics and increased its price target from $10 to $13.
Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13
Wedbush Adjusts Aclaris Therapeutics Price Target to $8
Wedbush has lowered its price target for Aclaris Therapeutics from $10 to $8 while maintaining an Outperform rating.
Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug
Aclaris Therapeutics announces positive Phase 1b trial data for ATI-052 in eczema and asthma alongside a $50 million public financing round.
Aclaris Therapeutics Prices $50 Million Public Offering
Aclaris Therapeutics announced the pricing of an underwritten public offering of common stock and pre-funded warrants expected to generate approximately $50 million in gross proceeds.